CACNA1A
protein-codingcalcium voltage-gated channel subunit alpha1 A, the group of Calcium voltage-gated channel alpha1 subunits
Gene summary
Voltage-dependent calcium channels mediate the entry of calcium ions into excitable cells, and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, and gene expression. Calcium channels are multisubunit complexes composed of alpha-1, beta, alpha-2/delta, and gamma subunits. The channel activity is directed by the pore-forming alpha-1 subunit, whereas, the others act as auxiliary subunits regulating this activity. The distinctive properties of the calcium channel types are related primarily to the expression of a variety of alpha-1 isoforms, alpha-1A, B, C, D, E, and S. This gene encodes the alpha-1A subunit, which is predominantly expressed in neuronal tissue. Mutations in this gene are associated with 2 neurologic disorders, familial hemiplegic migraine and episodic ataxia 2. This gene also exhibits polymorphic variation due to (CAG)n-repeats. Multiple transcript variants encoding different isoforms have been found for this gene. In one set of transcript variants, the (CAG)n-repeats occur in the 3' UTR, and are not associated with any disease. But in another set of variants, an insertion extends the coding region to include the (CAG)n-repeats which encode a polyglutamine tract. Expansion of the (CAG)n-repeats from the normal 4-18 to 21-33 in the coding region is associated with spinocerebellar ataxia 6. [provided by RefSeq, Jul 2016]
- CACNL1A4
- SCA6
- MHP1
- MHP
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~418.0 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0007163
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0014917
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0008457
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0018614
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0019113
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0018925
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0018614
Submitter: Illumina
Inheritance Pattern: AD
Disease ID:MONDO:0008457
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0020756
Submitter: Genomics England PanelApp
Inheritance Pattern: AD
Disease ID:MONDO:0014917
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0007163
Submitter: Genomics England PanelApp
Inheritance Pattern: AD
Disease ID:MONDO:0008457
Submitter: Genomics England PanelApp
Inheritance Pattern: AD
Disease ID:MONDO:0007163
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0020756
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0008457
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0016532
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0007163
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0014917
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0020756
Submitter: Ambry Genetics
Clinical Genomic Database (CGD)
Manifestation: Neurologic
Intervention: Neurologic; Pharmacogenomic
Rationale: Medical treatment (eg, 4-aminopyridine, acetazolamide, as well as other standard migraine-related medications to treat migraines) may be effective; In Migraine, familial hemiplegic 1, vasoconstricting agents (due to risk of stroke) and cerebral angiography (due to risk of precipitation of attack) should be avoided; In Spinocerebellar ataxia 6, ataxia may be managed medically (with acetazolamide); Vestibular symptoms may be managed medically (eg, with diphenhydramine, baclofen, and gabapentin. 4-aminopyridine)
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to CACNA1A variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001127222.2. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 39 | 818 | 21 | 878 | ||
| missense | 44 | 177 | 1661 | 307 | 10 | 2199 |
| nonsense | 74 | 37 | 3 | 114 | ||
| start loss | 1 | 1 | ||||
| frameshift | 147 | 63 | 19 | 229 | ||
| splice donor/acceptor (+/-2bp) | 23 | 58 | 4 | 85 | ||
| Total | 289 | 335 | 1726 | 1125 | 31 | 3506 |
Highest pathogenic variant AF is 0.000116978495
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001120694.1 | 47 | MANE Select | |
| Ensembl | ENSP00000353362.5 | 47 | MANE Select | |
| RefSeq | NP_000059.3 | 48 | Standard | |
| RefSeq | NP_001120693.1 | 47 | MANE Plus Clinical |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| cacna1ab | Danio rerio | Structure: slow muscle cell Quality: non-contractile abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Synaptic vesicle cycle - Homo sapiens (human)
- Retrograde endocannabinoid signaling - Homo sapiens (human)
- GABAergic synapse - Homo sapiens (human)
- Serotonergic synapse - Homo sapiens (human)
- Dopaminergic synapse - Homo sapiens (human)
Biological Process
- calcium ion transport
- positive regulation of cytosolic calcium ion concentration
- chemical synaptic transmission
- cell death
- regulation of ion transmembrane transport
Molecular Function
- amyloid-beta binding
- voltage-gated calcium channel activity
- calcium channel activity
- protein binding
- high voltage-gated calcium channel activity
Cellular Component
- nucleus
- cytoplasm
- plasma membrane
- voltage-gated calcium channel complex
- integral component of membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000360228
- Coding exons
- 47
- Length
- 417549
- Individuals with no LoFs
- 124643
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 12
- Defined
- 124655
- p
- 0.0000481
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 5.78 | 844 | 1.47e+3 | 0.575 | 0.0000976 | 16214 |
| Missense (PolyPhen) | 159 | 372.91 | 0.42638 | 3690 | ||
| Synonymous | -0.260 | 621 | 613 | 1.01 | 0.0000449 | 4918 |
| Loss of Function | 9.27 | 9 | 117 | 0.0767 | 0.00000664 | 1264 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.000066 | 0.000065 | rare |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.000056 | 0.000056 | rare |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.000084 | 0.000080 | rare |
| South Asian | 0.000034 | 0.000033 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to the 'high-voltage activated' (HVA) group and are specifically blocked by the spider omega-agatoxin-IVA (AC P54282) (By similarity). They are however insensitive to dihydropyridines (DHP). {ECO:0000250|UniProtKB:P54282, ECO:0000269|PubMed:10049321, ECO:0000269|PubMed:10753886, ECO:0000269|PubMed:11723274, ECO:0000269|PubMed:15293273, ECO:0000269|PubMed:19232643, ECO:0000269|PubMed:24836863, ECO:0000269|PubMed:26716990}.;
- Disease
- DISEASE: Spinocerebellar ataxia 6 (SCA6) [MIM:183086]: Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA6 is an autosomal dominant cerebellar ataxia (ADCA), mainly caused by expansion of a CAG repeat in the coding region of CACNA1A. There seems to be a correlation between the repeat number and earlier onset of the disorder. {ECO:0000269|PubMed:16325861, ECO:0000269|PubMed:20682717, ECO:0000269|PubMed:29053796, ECO:0000269|PubMed:8988170, ECO:0000269|PubMed:9302278, ECO:0000269|PubMed:9345107}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Migraine, familial hemiplegic, 1 (FHM1) [MIM:141500]: A subtype of migraine with aura associated with ictal hemiparesis and, in some families, cerebellar ataxia and atrophy. Migraine is a disabling symptom complex of periodic headaches, usually temporal and unilateral. Headaches are often accompanied by irritability, nausea, vomiting and photophobia, preceded by constriction of the cranial arteries. Migraine with aura is characterized by recurrent attacks of reversible neurological symptoms (aura) that precede or accompany the headache. Aura may include a combination of sensory disturbances, such as blurred vision, hallucinations, vertigo, numbness and difficulty in concentrating and speaking. {ECO:0000269|PubMed:10408532, ECO:0000269|PubMed:11409427, ECO:0000269|PubMed:11439943, ECO:0000269|PubMed:15032980, ECO:0000269|PubMed:18400034, ECO:0000269|PubMed:24836863, ECO:0000269|PubMed:26716990, ECO:0000269|PubMed:28900389, ECO:0000269|PubMed:8898206}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Episodic ataxia 2 (EA2) [MIM:108500]: An autosomal dominant disorder characterized by acetozolamide-responsive attacks of ataxia, migraine-like symptoms, interictal nystagmus, and cerebellar atrophy. {ECO:0000269|PubMed:10408533, ECO:0000269|PubMed:10987655, ECO:0000269|PubMed:11176968, ECO:0000269|PubMed:11723274, ECO:0000269|PubMed:12420090, ECO:0000269|PubMed:14718690, ECO:0000269|PubMed:15173248, ECO:0000269|PubMed:15293273, ECO:0000269|PubMed:18602318, ECO:0000269|PubMed:19232643, ECO:0000269|PubMed:20129625, ECO:0000269|PubMed:21696515, ECO:0000269|PubMed:8898206, ECO:0000269|PubMed:9302278}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Epileptic encephalopathy, early infantile, 42 (EIEE42) [MIM:617106]: A form of epileptic encephalopathy, a heterogeneous group of severe childhood onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. EIEE42 inheritance is autosomal dominant. {ECO:0000269|PubMed:27250579, ECO:0000269|PubMed:27476654}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.559
Intolerance Scores
- RVIS EVS
- -1.78
- RVIS percentile EVS
- 2.27
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.731
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | High | Medium | Medium |
| Primary Immunodeficiency | High | High | High |
| Cancer | High | High | High |